For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Pitavastatin 4mg Renal Impaired | Subjects with severe renal impairment (glomerular filtration rate \[GFR\] of 15 to 29 mL/min/1.73 m2, inclusive) who are not being treated with hemodialysis | None | None | 0 | 8 | 3 | 8 | View |
| Pitavastatin 4mg Healthy Subjects | Healthy subjects (GFR greater than or equal to 90 mL/min/1.73 m2) | None | None | 0 | 8 | 1 | 8 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Diarrhea | None | Gastrointestinal disorders | Medra | View |
| Nausea | None | Gastrointestinal disorders | MedDRA | View |
| Vomiting | None | Gastrointestinal disorders | MedDRA | View |
| Fatigue | None | General disorders | MedDRA | View |
| Myalgia | None | Musculoskeletal and connective tissue disorders | MedDRA | View |
| Polyuria | None | Renal and urinary disorders | MedDRA | View |